HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated the associations between TIL levels and magnetic resonance imaging (MRI) findings in patients with estrogen receptor (ER)-negative HER-2 positive breast cancer.
|
31109192 |
2020 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy.
|
31809240 |
2020 |
HER2-positive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The distinct subtypes of MYC;NeuNT tumors match existing subtypes of amplified-HER2, estrogen receptor-negative human tumors by molecular expression, identifying the preclinical utility of this murine model to interrogate subtype-specific differences in amplified-HER2 breast cancer.
|
31763993 |
2020 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, our analysis of public data revealed that Gpn3 overexpression was associated with a significant decrease in overall survival in patients with estrogen receptor-positive and Human epidermal growth factor receptor 2 (HER2+) breast cancer, supporting our proposal that targeting Gpn3 could potentially benefit patients with breast cancer.
|
31431135 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, and in a phosphoinositide 3-kinase, catalytic, alpha polypeptide mutation sub-population (PIK3CA+).
|
30860570 |
2019 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the combined effects of ruxolitinib and calcitriol on an estrogen receptor (ER)‑positive, human epidermal growth factor receptor 2 (HER2)‑positive, breast cancer cell line.
|
29436642 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Partial responses and durations of response of 12, 25, and 38 months in three cases with multiple metastases of ER positive and HER2 positive breast cancer were observed; all patients had been treated with 1-4 regimens of an anti-HER2 agent in combination with chemotherapy or an aromatase inhibitor before the initiation of fulvestrant.
|
30233207 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
For estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer with a single AUS-suspicious node and a positive lymph node needle biopsy (LNNB), sentinel lymph node biopsy (SLNB) is performed with a specimen X-ray documenting retrieval of the clipped node.
|
29868976 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene Oncotype DX<sup>®</sup> Breast Recurrence Score<sup>®</sup> (RS) assay has been prospectively validated as prognostic and predictive in node-negative, estrogen receptor-positive (ER+)/HER2- breast cancer patients.
|
29968028 |
2018 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the combination of miRNA profiles and ER status may improve the accuracy of pCR prediction in patients with HER2-positive breast cancer and enable the development of personalized treatment regimens.
|
28454317 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor positive (ER+) and HER2-negative (HER2-) breast cancer (BC) is the most common BC subtype, defined by expression of the ER and absence of HER2 amplification.
|
28448864 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The triple negative [estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (Her2)] breast cancer cell line MDA-MB-231 and ER/PR/HER-2-positive breast cancer cell line MCF-7 were cultured, transfected with Notch1-siRNA-overexpression plasmid and blank plasmid, and treated with different concentrations of paclitaxel, and then the cell proliferation activity and apoptosis rate as well as the mRNA expression of Caspase-3, Caspase-9 and Bcl-2 were determined.
|
28237486 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Objectives The objective was to examine if night shift work is a short-term risk factor for breast cancer, including combined estrogen receptor (ER) and human epidermal growth factor 2 (HER2) breast cancer subtypes.
|
27841916 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
They are triple-negative breast cancer, estrogen receptor (ER) and progesterone receptor (PR)-positive-HR positive breast cancer, and human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
|
29282680 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study assesses <sup>18</sup>F-FDG-PET/CT for patients with newly diagnosed estrogen receptor-positive/human epidermal growth factor receptor-negative (ER+/HER2-) and human epidermal growth factor receptor-positive (HER2+) breast cancer.
|
28456837 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.
|
26017482 |
2017 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
|
27090210 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p < 0.0001) and to have HR (ER and/or PgR)-positive (72 vs. 54 %; p < 0.0001) BC and less likely to have tumor >2 cm (T ≥ 2 cm 39 vs. 59 %; p < 0.0001), positive N (47 vs. 89 %; p < 0.0001) and a high G (61 vs. 67 %; p = 0.0241).
|
26531187 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postmenopausal ER+HER2+ breast cancer of stages II-III was eligible.
|
27491481 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several SNPs were associated with all, ER-positive, and HER2-positive breast cancers; however, after correcting for multiple comparisons (i.e., p < 0.0008), only rs2293554 was statistically significantly associated with HER2-positive breast cancer (OR = 1.98, 95% CI 1.34-2.92, uncorrected p = 0.0005).
|
26758508 |
2016 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we dissect the roles of ER-mediated transactivation and transrepression in the regulation of invasiveness of ER+/HER2+ breast cancer cells by E2.
|
25582774 |
2015 |
HER2-positive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with ER/HER2-positive breast cancer have a poor prognosis and are less responsive to selective estrogen receptor modulators; this is presumably due to the crosstalk between ER and HER2.
|
24866893 |
2014 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to identify a panel of circulating microRNAs with the potential to serve as biomarkers for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 (HER2)- breast cancer.
|
25179838 |
2014 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The collective data are sufficiently strong at this point to propose that ER status defines two distinct subtypes within HER2-positive breast cancer, and we highlight the implications of this knowledge in future research, including understanding of the basic biology of HER2-positive breast cancer and the design of future clinical trials.
|
23022997 |
2013 |
HER2-positive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acquired endocrine resistance in estrogen receptor (ER)alpha+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer has been associated with modest adaptive increases in HER2, although exactly how aberrant HER2 signaling affects the ERalpha pathway is poorly understood.
|
20179226 |
2010 |